Hematologic Malignancies Congress

Managing Chronic Myeloid Leukemia Treatment

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

New Model Helps Guide Treatment Options in CLL

Certain characteristics of patients with CML can affect therapeutic outcomes.

Dr. Erba Describes Proper Diagnostic Testing of CML

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

By Harry Erba, MD, PhD

Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCL

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

By Kieron Dunleavy, MD

Current Trends in the Treatment of Newly Diagnosed Myeloma

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

$New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dr. Ansell on Waldenstrom Macroglobulinemia Types

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

By Stephen Ansell, MD, PhD